

GPTHEALTH/CS/SE/2024-25

June 25, 2024

<p>The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544131</p>	<p>National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: GPTHEALTH</p>
--	--

Dear Sir/Madam

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This is to inform you that our Company has entered into the following Agreements on June 25, 2024:

SL No.	Type of Agreement	Parties to the Agreement	Background
1	Novation Agreement	1.GPT Healthcare Limited (“GHL”) 2.Amrish Oncology Services Private Limited (“AOSPL”) and International Oncology Services Private Limited (“IOSPL”).	<p>GPT Healthcare Limited (“GHL”), a company registered under the provisions of the Companies Act, 1956, is engaged in running a chain of multi-specialty hospitals under the brand name of “ILS Hospitals”</p> <p>Amrish Oncology Services Private Limited (“AOSPL”), a company registered under the provisions of the Companies Act, 1956, is an established institute having the exclusive license and right to run, operate, manage, and market the cancer care healthcare institutions. AOSPL has been instrumental in providing cancer care to the patients across the country of India.</p> <p>GHL had earlier entered into a Cancer Care Department Management Agreement with AOSPL dated September 1, 2023, read with the Memorandum of Understanding dated September 6, 2023 (“Original Agreements”) for setting up and operate Cancer Care Department at the Hospital of GHL namely ILS Hospitals, Agartala.</p> <p>The AOSPL and IOSPL have entered into a business transfer agreement on May 30, 2024 whereby AOSPL has transferred and the IOSPL has purchased for a consideration, the business and right to run, operate, manage, and market the cancer care division at ILS Hospitals, Agartala of GHL.</p> <p>Therefore, the Parties have executed this agreement and have agreed that as and from the Execution Date of this novation agreement, the “Original Agreements” shall be novated to IOSPL and the IOSPL shall be bound by the terms of the Original Agreements in place of the AOSPL.</p>
2	Addendum Agreement	1.GPT Healthcare Limited (“GHL”) and International Oncology Services Private Limited (IOSPL)	The GHL, AOSPL and IOSPL (“Parties”) have entered into Novation Agreement dated June 25, 2024 for novation of Cancer Care Department Management Agreement such that IOSPL is substituted in place of AOSPL and AOSPL is released

			<p>and discharged from its obligations to GHIL under the Original Agreements.</p> <p>In view of the revised understanding between GHIL and IOSPL and to bring further clarity on the same, GHIL and IOSPL have executed the Addendum Agreement.</p>
--	--	--	---

The details as required under Part A of Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with relevant circular has been enclosed as **Annexure I**.

Kindly take the aforesaid information on record and oblige.

Thanking You,

Yours sincerely,

For GPT Healthcare Limited

Ankur Sharma
Company Secretary and Compliance Officer
M.No A31833

Annexure-I

SNo	Name(s) of parties with whom the agreement is entered	Details
1	Name(s) of parties with whom the agreement is entered	<p>1. Novation Agreement: GPT Healthcare Limited (“GHL), Amrish Oncology Services Private Limited (“AOSPL”) and International Oncology Services Private Limited (“IOSPL).</p> <p>2. Addendum Agreement: GPT Healthcare Limited (“GHL) and International Oncology Services Private Limited (“IOSPL).</p>
2	Purpose of entering into the agreement	<p>1. Novation Agreement: IOSPL is substituted in place of AOSPL and AOSPL is released and discharged from its obligations to GHL under the Original Agreements.</p> <p>2. Addendum Agreement: In view of the revised understanding between GHL and IOSPL and to bring further clarity on the same, GHL and IOSPL have executed the Addendum Agreement.</p>
3	Shareholding, if any, in the entity with whom the agreement is executed	Nil
4	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc	Not applicable. No such conditions.
5	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	No
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length	The transaction is not a related party transaction.
7	In case of issuance of shares to the parties, details of issue price, class of shares issued	There is no new issue of shares.
8	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	Agreement is being entered with a third party and there is no conflict of interest and no nominee is on the board of Directors of the Company.
9	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	<p>a) name of parties to the agreement; as stated above</p> <p>b) nature of the agreement; Novation Agreement and Addendum Agreement.</p> <p>c) date of execution of the agreement; June 25, 2024</p> <p>d) details of amendment and impact thereof or reasons of termination and impact thereof; as mentioned above.</p>